Subscribe
Conference Correspondent
Ujjaini and colleagues reported findings of a phase 1 study evaluating the triplet combination of the Bruton’s tyrosine kinase inhibitor ibrutinib plus rituximab and lenalidomide as a frontline regimen in patients with follicular lymphoma.
Researchers presented preliminary results of a randomized, phase 2 (PYRAMID) study that evaluated the efficacy and safety of frontline R-CHOP versus VR-CHOP in patients with the non-germinal center B-cell–like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL).
The results of a phase 3, randomized, placebo-controlled study that evaluated the PI3K-delta inhibitor idelalisib in combination with standard bendamustine/rituximab (BR) versus BR alone in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) were reported.
Preliminary results of a phase 2 trial of the selective inhibitor of spleen tyrosine kinase (Syk) entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) were reported.
Stilgenbauer and colleagues reported on the impact of baseline genetic features and prognostic factors on efficacy and survival outcomes in the phase 2 RESONATE-17 study (PCYC-1117) that evaluated the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) harboring the deletion 17p (del17p) cytogenetic abnormality.
Researchers presented interim results of the CLL2-BIG trial that evaluated the anti-CD20 monoclonal antibody obinutuzumab plus the Bruton’s tyrosine kinase inhibitor ibrutinib following debulking with bendamustine in patients with high tumor burden to reduce the risk of severe infusion-related reactions (IRRs) in patients with chronic lymphocytic leukemia and high tumor burden.
Safety and efficacy results of the randomized phase 3 RAY (MCL3001) study that compared Bruton’s tyrosine kinase inhibitor ibrutinib versus temsirolimus in patients with relapsed and/or refractory mantle-cell lymphoma (MCL) were reported.
Researchers presented results of an open-label phase 2 trial (PCYC-1125-CA) that evaluated the Bruton’s tyrosine kinase inhibitor ibrutinib plus rituximab combination therapy in treatment-naïve patients with follicular lymphoma.
Subgroup analysis is presented of previously untreated patients in the ongoing, nonrandomized, multicohort phase 3b GREEN study that is evaluating the novel anti-CD20 monoclonal antibody obinutuzumab plus bendamustine treatment in patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).
Tedeschi and colleagues presented results of the head-to-head efficacy and safety comparison of the Bruton’s tyrosine kinase inhibitor ibrutinib versus chlorambucil treatment in the randomized, phase 3 RESONATE-2 trial of treatment-naïve patients ≥65 years of age with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
Page 1 of 2
Results 1 - 10 of 20
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology